The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
